Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: A GERCOR study

Oncologist

Volumn 16, Issue 9, 2011, Pages 1228-1338

  Chibaudel, Benoist ^a,b   Bonnetain, Franck ^b,c,d   Tournigand, Christophe ^a,e   Bengrine Lefevre, Leila ^a   Teixeira, Luis ^a   Artru, Pascal ^f   Desramé, Jérôme ^f   Larsen, Annette K ^a,e   André, Thierry ^a,e   Louvet, Christophe ^a,g   de Gramont, Aimery ^a,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b GERCOR   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d Chu   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f Centre Orthopédique Santy Hôpital Privé Jean Mermoz   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Chemotherapy; Colorectal cancer; Prognostic model

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; L-LACTATE DEHYDROGENASE; LEUCOVORIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80053183054     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0039     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J et al. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 1995;82:1397-1400.
3. Giacchetti S, Perpoint B, Zidani R et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol 2000;18:136-147.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorec-tal Cancer. J Clin Oncol 2000;18:2938-2947.
5. Saltz L, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
6. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
7. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19: 4097-4106.
8. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
9. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
10. Colucci G, Gebbia V, Paoletti G et al. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4inthe Treatment ofAdvanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridion-ale. J Clin Oncol 2005;23:4866-4875.
11. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: arandomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.
12. Giacchetti S, Bjarnason G, Garufi C et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluoroura-cil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24:3562-3569.
13. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-flu-orouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805.
14. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-4223.
15. Falcone A, Ricci S, Brunetti I et al. Phase III Trial of Infusional Fluorou-racil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Onco-logico Nord Ovest. J Clin Oncol 2007;25:1670-1676.
16. Köhne CH, Cunningham D, Di CF et al. Clinical determinants ofsurvival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13: 308-317.
17. Chibaudel B, Maindrault F, Lledo G, et al. Cana planned treatment break be given to patients with unresectable metastatic colorectal cancer? Results of the GERCOR OPTIMOX 2 study. J Clin Oncol 2009;27:5727-5733.
18. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-346.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-473.
21. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34B:187-220.
22. Harrell FE, Lee KL, Mark DB et al. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
23. Steyerberg EW, Vickers AJ, Cook NR et al. Assessing the performance of prediction models a framework for traditional and novel measures. Epidemiology 2010;21:128-138.
24. de Gramont A, Haller DG, Sargent DJ et al. Toward efficient trials in colo-rectal cancer: The ARCAD Clinical Trials Program. J Clin Oncol 2010;28: 527-530.
25. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 1983;74:786-794.
26. Tas F, Aykan F, Alici S et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001;24:547-550.
27. Tas F, Aydiner A, Demir C et al. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001;24:376-378.
28. Nisman B, Barak V, Hubert A et al. Prognostic factors for survival in met-astatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res 2003;23:1939-1942.
29. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas. Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9:211-219.
30. Dimopoulos MA, Barlogie B, Smith TL et al. High serum lactate dehydro-genase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931-935.
31. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/ 5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 2005;23:16S (abstr LBA3).
32. Sargent DJ, Köhne CH, Sanoff HK et al. Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. J Clin Oncol 2009;27:1948-1955.
33. Chibaudel B, Tournigand C, Artru P et al. FOLFOX in patients with met-astatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol 2009;20: 1383-1386.
34. Tournigand C, Andre T, Bachet J et al. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): subgroup analysis of the MOSAIC trial. J Clin Oncol 2010;28:15S (abstr 3522).
35. Tournoux-Facon C, Paoletti X, Barbare JC et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2011;54:108-114.
36. Díaz R, Aparicio J, Gironés R et al. Analysis of prognostic factors and applicability of Köhne's prognostic groups in patients with metastatic colo-rectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005;5:197-202.
37. Sanoff HK, Sargent DJ, Campbell ME et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-5727.
38. Efficace F, Innominato PF, Bjarnason G et al. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2008;26:2020-2026.
39. Quinten C, Coens C, Mauer M et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10:865-871.
40. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
41. di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAFisrequired for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
42. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-5930.